Discover and read the best of Twitter Threads about #tmb
Most recents (8)
1) Welcome to a new #accredited #tweetorial, "Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC," featuring the highlights of a symposium presented at the #ESMOIO22 congress.
@myESMO #LCSM #FOAMed
@myESMO #LCSM #FOAMed
2) The faculty for this outstanding program were @peters_solange (Chair) 🇨🇭, @HosseinBorghaei 🇺🇸, Natasha Leighl MD 🇨🇦, and @dplanchard 🇫🇷. A truly international roster of experts in #oncology!
Don't miss prior accredited courses in this space at oncologytweetorials-ce.com/category/lung-….
Don't miss prior accredited courses in this space at oncologytweetorials-ce.com/category/lung-….
3) This program is supported by an educational grant from Sanofi. Statement of accreditation and author disclosures are at oncologytweetorials-ce.com/disclosures/.
Two recent preprints report almost opposite views on the use of #TMB in IO therapy.
For: @CharlesSwanton et al researchsquare.com/article/rs-764…
Against: @leonidmirny biorxiv.org/content/10.110…
Who's right...answers on a postcard please!
For: @CharlesSwanton et al researchsquare.com/article/rs-764…
Against: @leonidmirny biorxiv.org/content/10.110…
Who's right...answers on a postcard please!
For (1) Clonal TMB had the strongest effect size across all 15 studies in the (Odds Ratio for “CR/PR” vs “SD/PD” = 1.88, 95% confidence interval [1.52 – 2.33], p=8.08 x 10-9).
For (2) They propose a 12-feature multivariate model (AUC of 0.86 in a pan-tumor cohort), which was superior to TMB alone (AUC=0.59). Improved AUC was confirmed in KEYNOTE-028 and Liu et al. NMED 2019. Their model identifies subgroups with <5%) or ~50% likelihood of response
#ESMO20 Grateful for the chance to present characterization of long-term #SCLC survivors with atezolizumab and carboplatin/etoposide in IMpower 133. #LCSM @IASLC @OncoAlert
#ESMO20 IMpower 133 was a placebo controlled, double blind, randomized phase III trial for patients with treatment naive ES-SCLC that showed the addition of atezolizumab to 1L carboplatin + etoposide improved PFS and OS, leading to FDA and EMA approval in 2019. #LCSM @OncoAlert
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
#AACR20 Outcomes in KEYNOTE-189 (1L carbo + pem + pembro in #NSCLC) by STK11 and KEAP1 status presented by Shirish Gadgeel. Analysis on a (sizable) subset of the ITT showed STK11mt/KEAP1wt 8.7%, STK11wt/KEAP1mt 13.5%, double STK11/KEAP1 mt 10%. #LCSM #OncoAlert
#AACR20 STK11 and KEAP1 mutations associated with lower PDL1 expression and higher #TMB. #LCSM #OncoAlert
#AACR20 Addition of pembro to chemo improved RR independent of STK11 and KEAP1 mutation status. #LCSM #OncoAlert
#ASCO20 Very promising results from PrECOG 0505 trial presented by @FordePatrick: Single arm phase II of durvalumab with cis/pem as 1L treatment for unresectable pleural mesothelioma (#MPM) #OncoAlert
#ASCO20 PrE0505 enrolled 55 patients (75% epithelioid) in 1y and treated with 6 cycles of standard cis/pem with durva 1120mg q3w followed by durva maintenance therapy (until PD). #OncoAlert
#ASCO20 Impressive OS numbers here with addition of durvalumab to cis/pem in #MPM with median of 20.4m and a 1y OS rate of 70.4%. Median PFS was 6.7m and RR was 56% (in the Australian DREAM trial RR was 48%). #OncoAlert
#OncoAlert Randomized cohort from CheckMate 032 now available @JTOonline. Included 243 patients with relapsed #SCLC (1-2 prior lines), no PDL1 selection. Randomized 3:2 to nivo 3mg/kg q2w or nivo 1mg/kg with ipi 3mg/kg q3w x 4 (then nivo maint). #LCSM
jto.org/article/S1556-…
jto.org/article/S1556-…
@JTOonline #OncoAlert Primary endpoint ORR (side bar: what is the best endpoint?). Early results from @ASCO 2017 showed ORR 12% nivo and 21% with nivo/ipi with improved 3 month PFS rate but no diff in 3 month OS, presented then as bar graphs instead of KM curves (?!)
@JTOonline @ASCO #OncoAlert Now, with a median f/u of 11.9m, we see similar trends. ORR 11.6% with nivo (DOR 15.8m) and 21.9% with nivo/ipi (DOR 10m). mPFS similar (1.4 and 1.5m) but landmark PFS slightly better with nivo/ipi (3m: 32% vs 22%; 6m: 16% vs 22%, 1y: 10% vs 12%). Meaningful? #LCSM
#ESMO19 Debate (“boxing”) on use of IO biomarkers in #NSCLC. @Alfdoc2 gives the pro position. Highlights KN024 and recent IMp110 using PDL1 and the important @IASLC Blueprint study with @fred_hirsch. Draws parallels with targeted therapy paradigms. #OncoAlert Nice job Alfredo!
#ESMO19 The contra position by Enriqueta Felip. KN024 great but note screen failures, maybe lack of generalizability. Chemo-immunotherapy combo very effective in PDL1 unknown. Utility of #TMB limited. Case made for IO in some form for everyone. #OncoAlert Also well done!
#ESMO19 Enjoyed the boxing format - discussion led by @peters_solange pushing @Alfdoc2 and @EFelipSEOM19 on what will the future hold. Great session chaired by @matteolambe - more lively way to present and discuss the state of the art. #OncoAlert
